Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth.
Share this article
Corporate
Score 65
Bullish
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth
Mar 17, 2026 09:27 UTC
GILD, XLV, IHF
Medium term
Related Articles
Score 78
Bullish
Delta Raises Revenue Guidance Amid Strong Travel Demand, Despite $400M Q4 Hit
Mar 17, 11:27
Score 85
UniCredit Gave Rome a Heads-Up on Commerzbank €35 Billion Offer
Mar 17, 11:17
Score 85
Bullish
Nebius intends to raise $3.75 billion via convertible loan following Meta, Nvidia deals
Mar 17, 11:01
Score 65
Bearish
Starbucks shareholders push to oust board members over stalled union talks
Mar 17, 11:00
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.